Eikon Therapeutics, Inc. Common Stock
EIKN
Get informed when a big investor buys or sells
+ FollowMarket Cap$484.54M
Close$
$-2.82
134% downside
Current Fair Value
134% downsideOvervalued by 134% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $484.54 Million |
|---|---|
| Enterprise Value | $593.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.16 |
| Beta | 0.94 |
| Outstanding Shares | 54,148,887 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.93 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.04 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | 0.54 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-1.58
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.74
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 49.26%▲ 5.40% |
|---|---|
| Total Invested | $346.50M▲ 37.93% |
| Investors Holding | 78▲ 26.00% |
ESG Score
No data
About Eikon Therapeutics, Inc. Common Stock
484 employees
CEO: Roger Perlmutter Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of pro...